Fig. 6.

In vivo therapeutic efficacy of AaLS/LOX/CAT. a Timeline of the establishment of the CT26 allograft mouse model, the intratumoral injections of samples, and the tumor size measurements. b Tumor sizes were measured in mice treated with PBS (black squares), AaLS (red circles), or AaLS/LOX/CAT (blue triangles) every two or three days using a caliper. Data are averages ± standard deviations (SD); n = 4 per group; *p = 0.015. c Body weights of mice treated with PBS (black squares), AaLS (red circles), or AaLS/LOX/CAT (blue triangles). d Tumors, hearts, kidneys, livers, lungs, and spleens collected from sacrificed mice treated with PBS or AaLS/LOX/CAT were fixed in 10% formalin, embedded in paraffin, and sectioned. Then, the tissue sections were stained with H&E, after which images were captured using an Olympus virtual microscope (scale bar, 100 μm). e Representative FACS dot plots showing CD64⁺ macrophages, CD206⁺ or CD86⁺ macrophages gated on CD11b⁺F4/80⁺ cells, and Ly6G⁺ neutrophils gated on CD3^–CD11b⁺ cells in tumors of indicated conditions. Graph on the right shows the quantification of the frequency of CD64⁺, CD206⁺, CD86⁺ and Ly6G⁺ cells (n = 3). *p < 0.05, **p < 0.01, ns, not significant, by student’s t-test